Journal of Diabetes Investigation, 2020 Aims/Introduction Tofogliflozin is a potent and highly selective sodium–glucose cotransporter 2 inhibitor, and is currently used to treat patients with type 2 diabetes mellitus. We designed a 3‐year study of tofogliflozin in patients with type 2 diabetes
Kazunori Utsunomiya +9 more
doaj +1 more source
SGLT2 Inhibitor-Associated Changes in Urinary Volatile Organic Compounds in Diabetic Kidney Disease: A Comprehensive Study. [PDF]
Nephrology (Carlton)This study analysed urinary volatile organic compounds (VOCs) to identify non‐invasive biomarkers for monitoring metabolic mechanisms of SGLT2 inhibitor renoprotection in diabetic kidney disease. The results revealed significantly higher levels of urinary acetone and 2‐pentanone in the treated group, indicating that these ketone‐related VOCs serve as ...
Hara R +6 more
europepmc +2 more sources
Canagliflozin, a New Sodium-Glucose Co-Transporter 2 Inhibitor, in the Treatment of Diabetes [PDF]
, 2013 Purpose. The published evidence on the pharmacology, pharmacodynamics, pharmacokinetics, safety, and efficacy of a promising investigational agent for managing type 2 diabetes is evaluated. Summary.
Kolanczyk, Denise M. +2 more
core +2 more sources
Impacts of Sodium/Glucose Cotransporter-2 Inhibitors on Circulating Uric Acid Concentrations: A Systematic Review and Meta-Analysis [PDF]
, 2022 Background: Several trials have assessed the antihyperglycemic effects of sodium/glucose cotransporter-2 inhibitors (SGLT2i) in patients with type 2 diabetes mellitus (T2DM).
Akbari, Abolfazl +3 more
core +1 more source
Therapeutic potential of tofogliflozin on nephrotic syndrome secondary to diabetic nephropathy [PDF]
Journal of Cardiology Cases, 2017 Diabetic nephropathy (DN) is a critical complication in patients with type 2 diabetes and regarded as a progressive disorder with a poor prognosis. The degree of albuminuria is associated closely with worse renal and cardiovascular outcomes. It is therefore important to achieve remission of proteinuria to avoid progression of DN and improve outcomes ...
Atsushi Tanaka +3 more
openaire +2 more sources
Lack of Evidence for a Harmful Effect of Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitors on Fracture Risk among Type 2 Diabetes Patients: A Network and Cumulative Meta-Analysis of Randomized Controlled Trials [PDF]
, 2016 Aim To evaluate the comparative effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on risk of bone fracture in patients with type 2 diabetes mellitus (T2DM).
Hsu, Y. H. +6 more
core +2 more sources
Cardiac ischemia-reperfusion injury under insulin-resistant conditions: SGLT1 but not SGLT2 plays a compensatory protective role in diet-induced obesity [PDF]
, 2020 東京慈恵会医科大学博士 (医学)doctoral ...
吉井, 顕
core +1 more source
Journal of Diabetes Investigation, 2020 Aims/Introduction This subanalysis aimed to assess the safety and effectiveness of tofogliflozin by using data from the Japanese Study of Tofogliflozin with Type 2 Diabetes Mellitus Patients in an Observational Study of the Elderly to categorize elderly ...
Kohei Kaku +6 more
doaj +1 more source
Diabetology, 2022 Nocturia is a common disease in patients with type 2 diabetes mellitus that can reduce the quality of life. Sodium glucose co-transporter 2 (SGLT2) inhibitors increase the urine volume and are often discontinued when polyuria occurs, although ...
Hanako Nakajima +19 more
doaj +1 more source
Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin [PDF]
Diabetes, Obesity and Metabolism, 2018 An integrated analysis was performed with data from 4 phase 2 and phase 3 studies of tofogliflozin in which patients with type 2 diabetes mellitus received the sodium‐glucose cotransporter 2 inhibitor tofogliflozin for up to 24 weeks. Sex differences, baseline haemoglobin A1c (HbA1c) and serum uric acid (UA) levels, and log
Motoshi Ouchi +13 more
openaire +2 more sources